Czechia

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190

OptimUM-10 – Darovasertib before treatment for primary uveal melanoma Phase: Phase 3Trial ID: NCT07015190Treatment: DarovasertibStage: Primary uveal melanoma – the cancer must not have spread to other parts of the bodyUK locations: University College London Hospital and The Clatterbridge Cancer Centre, Liverpool What is this trial looking at? OptimUM-10 is investigating whether giving a drug called darovasertib before the usual treatment

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190 Read More »

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690 Read More »